SCHEMBL24723850

SCHEMBL24723850

CC(=O)c1ccc(S(=O)(=O)N(C)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.42
CA9 Q16790 3/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA14 Q9ULX7 1/20 0.42
KMT2A Q03164 4/20 0.42
HSD11B1 P28845 1/20 0.41
ALDH1A1 P00352 4/20 0.40
MAPT P10636 3/20 0.40
MEN1 O00255 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
HTT P42858 2/20 0.40
NR1I2 O75469 1/20 0.40
PKM P14618 1/20 0.40
RECQL P46063 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
STS P08842 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1864283 0.84 ALDH1A1 (0.51) CA12CA9ALDH1A1MAPTHTT
SCHEMBL9986889 0.83 KMT2A (0.46) KMT2AHSD11B1ALDH1A1MEN1SMN1; SMN2
SCHEMBL22517147 0.83 CA12 (0.40) CA12CA9CA1CA2CA14
SCHEMBL1858049 0.83 ALDH1A1 (0.39) CA12CA9CA1CA2CA14
SCHEMBL28034923 0.83 HSD11B1 (0.56) KMT2AHSD11B1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1858895 0.79 HSD11B1 (0.39) CA12CA9CA1CA2CA14
SCHEMBL24723852 0.79 NR1I2 (0.40) CA12CA9CA1CA2CA14
SCHEMBL31036586 0.78 MMP13 (0.35) CA12CA9CA1CA2CA14
SCHEMBL22517138 0.77 LMNA (0.57) KMT2AALDH1A1MEN1HTTLMNA
SCHEMBL1866007 0.75 PTPN11 (0.38) CA12CA9CA1CA2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) 2024-08-29 US disclosed
WO-2022253259-A1 FUSED HETEROCYCLIC DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287070-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 CA12 3792/4885CA9 3258/4885CA1 4828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.